Source: https://astrinbio.com/products
Language: en

# First-in-class products built on **first-in-class science**

Astrin's platform enables non-invasive cancer diagnostics that span early screening to therapy selection — all from blood.

## The blood test built to support breast cancer detection for women - especially with dense breasts.

## The Problem

### Most common cancer

Breast cancer is the most common cancer and the second most common cause of cancer death.

*Source: [Cancer Statistics 2025 (Siegel et al.)](https://pubmed.ncbi.nlm.nih.gov/39817679/)*

### 1 in 8 women

1 in 8 women in the U.S. will develop breast cancer in their lifetime.

*Source: [ACS](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html) / [Cancer Statistics 2025](https://pubmed.ncbi.nlm.nih.gov/39817679/)*

### Screening gap

Only \~66% of women over 40 receive recommended breast cancer screening.

*Source: [CDC](https://www.cdc.gov/nchs/hus/topics/mammography.htm)*

### Dense breasts

About 50% of women have dense breasts.

*Source: [Various epidemiologic sources](https://www.cancer.gov/types/breast/screening/dense-breasts)*

### Higher risk

Women with extremely dense breasts have a 1.8x to 2.4x higher risk of breast cancer than women with fatty breasts.

*Source: Holt DB, JAMA 2026 / Lynge E, et al. Int J Cancer 2023*

### How does it work?

Certitude uses Astrin's patented deep proteomic platform to distinguish healthy individuals from patients with early-stage breast cancer, all from a small blood sample.

After a simple blood draw, Astrin's AI platform profiles the full proteome, more than 9,000 proteins in a single run, to detect shifts in cellular activity and cancer signals that other tests may miss.

### How we are performing:

### Undiagnosed Breast Cancer

For every **1,000** women with dense breasts, **17** have undiagnosed breast cancer.

### 3D Mammogram

3D Mammograms will detect **5** instances or fewer.

### Certitude®

**Certitude®** will detect **>2×** as many instances as 3D Mammograms.

### Sensitivity & Specificity at a Glance

Compare published sensitivity and specificity across 3D mammography, ultrasound, CEM, and MRI for women with dense breasts. These data do not come from a head-to-head study but provide a comparative side-by-side view.

| Imaging method                    | Sensitivity | Specificity |
| --------------------------------- | ----------- | ----------- |
| 3D Mammogram                      | 39.1%       | 90.3%       |
| Ultrasound                        | 38%         | 96%         |
| Contrast-enhanced mammogram (CEM) | 90.6%       | 74%         |
| MRI                               | 97%         | 69%         |

* [Gilbert (Lancet 2025)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(25\)00582-3/fulltext)

* [Comstock (JAMA 2020)](https://jamanetwork.com/journals/jama/fullarticle/2761645)

* [Pötsch (Radiology 2020)](https://pubs.rsna.org/doi/epdf/10.1148/radiol.212530)

## What people are saying

### Women love it

> I did everything right — yearly mammograms, ultrasounds, follow-ups — and still my cancer was missed. Knowing a blood test could find what imaging overlooked gives me hope for the future. I want other women to have every possible chance to catch cancer early.

> As someone with dense breasts, I have never felt like I had any clarity after my mammograms. Knowing that there is a test that could actually work for me gives me new found hope for me and all women who are at high risk for breast cancer.

### Doctors are ready for it

> Too many women with dense breasts are left without clear answers after their annual screening. Certitude offers something we’ve needed — a simple, accessible test that can help detect cancer earlier and provide greater clarity. Certitude represents a meaningful and long-awaited advancement — one that can help physicians intervene sooner, reduce anxiety, and guide more confident clinical decision-making.
>
> **\~ Dr. Barbara Levy**\
> Chief Medical Officer at Visana Health and Clinical Professor at George Washington University and UC San Diego Health

> Mammography remains our most powerful population-level screening tool, but it is not perfect — particularly for the many women with dense breasts. A blood-based test that can identify molecular signals of cancer before they’re visible on imaging has the potential to fundamentally reshape the breast cancer screening paradigm.
>
> **\~ Dr. Ben H. Park**\
> Prominent breast cancer physician-scientist

### Get started with Certitude®

Certitude is available for physician orders and direct-to-consumer requests. [Create an account](https://order.certitudetest.com/sign-up) to check eligibility and request a test, or visit [Certitude for physicians](https://certitudetest.com/hcp) to set up ordering for your practice. Availability depends on eligibility and location.

## One platform. Built to keep up with biology.

Cancer evolves constantly. Proteins reflect those changes in real time. What once demanded invasive biopsies, scattered tests, and long delays now comes from a single, proteome-guided platform with a simple blood draw. Astrin integrates machine learning and cancer biology to deliver real-time insight from plasma at every stage of care. From initial detection to long-term monitoring, our platform helps clinicians stay out in front. When cancer shifts, we move faster to stay one step ahead. In partnership with leading healthcare systems, academic medical centers and pharma companies, we are advancing cancer care through innovation in early detection and precision medicine.

## Contact

Hours of operation:
